Skip to main content

4 Result(s)

within Brian G. M. Durie Remove this filter English Remove this filter Oncology Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy

    Objective methods have been developed to quantitate results of the in vitro human tumor stem cell assay, the degree of the association between the in vitro assay and clinical response as well as the likelihood...

    Thomas E. Moon, Sydney E. Salmon, Carolyn S. White… in Cancer Chemotherapy and Pharmacology (1981)

  2. No Access

    Article

    Treatment of patients with refractory myelogenous leukemia with BCOMM [1,3-bis-chloro(2-chloroethyl)-1-nitrosourea (BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methyl-glyoxal bis-guanylhydrazone (MGBG)]

    Ten patients with AML refractory to anthracyclines and cytosine arabinoside were treated with vincristine 1.4 mg/m2 and methotrexate (MTX) 2.5 gm/m2 by intravenous (IV) bolus on day 1 [citrovorum factor (CF) resc...

    Terence S. Herman, Brian G. M. Durie… in Cancer Chemotherapy and Pharmacology (1982)

  3. No Access

    Article

    Phase II evaluation of bisantrene in refractory multiple myeloma

    Brian G. M. Durie, John Crowley, Charles A. Coltman Jr.… in Investigational New Drugs (1991)

  4. Article

    Open Access

    Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

    Daratumumab plus lenalidomide and dexamethasone (D-Rd) and bortezomib plus lenalidomide and dexamethasone (VRd) are commonly used treatment combinations for transplant-ineligible (TIE) patients with newly diag...

    Brian G. M. Durie, Shaji K. Kumar, Eric M. Ammann, Alex Z. Fu… in Advances in Therapy (2024)

    Download PDF (629 KB) View Article